Results 121 to 130 of about 134,036 (314)

Intravenous lanadelumab for the treatment of moderately ill COVID‐19 patients

British Journal of Clinical Pharmacology, EarlyView.
Aims Kallikrein‐kinin system (KKS) dysregulation is hypothesized to play a pathogenetic role in COVID‐19‐associated pulmonary oedema. To investigate the efficacy and safety of intravenous lanadelumab, a monoclonal antibody that inhibits plasma kallikrein, in COVID‐19, we conducted a phase 2, open‐label, randomized‐controlled, proof‐of‐concept ...
Job J. Engel, Christine van Linge, W. Joost Wiersinga, Ilse J. E. Kouijzer, Quirijn de Mast, Robert‐Jan Hassing, Danique J. H. Huijbens, Helen L. Leavis, Roger Schutgens, Coen Maas, Kit C. B. Roes, Frank L. van de Veerdonk, Roger Brüggemann   +12 more
wiley   +1 more source

Pharmacological effects of raas blockade in ischemic nephropathy [PDF]

, 2016
Background: The management of ischemic nephropathy due to atherosclerotic renal artery stenosis has become increasingly conservative in the modern era, with current guidelines recommending optimized medical therapy as the initial step.
Barbano, Biagio, Cianci, Rosario, Coppolino, Giuseppe, Di Mario, Francesca, Farrah, Tariq E., Fuiano, Giorgio, Gigante, Antonietta, Rivoli, Laura, Rosato, Edoardo   +8 more
core   +1 more source

Possible therapeutic repositioning of valproic acid: From epileptic seizures to acute kidney injury

British Journal of Clinical Pharmacology, EarlyView.
Valproic acid, an anticonvulsant, may be repositioned to prevent acute kidney injury due to ischemia followed by reperfusion. It preserves renal functions, electrolyte homeostasis and active sodium transport in kidney tubules, and blocks the onset of hypertension.
Danilo Alves‐Bezerra, Luiza B. Negreiros, Amaury Pereira‐Acácio, Isadora G. Almeida, João P. M. Veloso‐Santos, Jarlene A. Lopes, Glória Costa‐Sarmento, Humberto Muzi‐Filho, Adalberto Vieyra   +8 more
wiley   +1 more source

Novel perspectives in redox biology and pathophysiology of failing myocytes: modulation of the intramyocardial redox milieu for therapeutic interventions - A review article from the Working Group of Cardiac Cell Biology, Italian Society of Cardiology [PDF]

, 2016
The prevalence of heart failure (HF) is still increasing worldwide, with enormous human, social, and economic costs, in spite of huge efforts in understanding pathogeneticmechanisms and in developing effective therapies that have transformed this ...
Angelini, Annalisa, Arcaro, Alessia, Chimenti, Cristina, Crotti, Lia, Giordano, Carla, Mancardi, Daniele, Pirozzi, Flora, Tocchetti, Carlo G., Torella, Daniele   +8 more
core   +5 more sources

Increasing the reporting of adverse drug reaction‐related hospitalizations using an ICD‐10‐based identification workflow: A multicentre study from Switzerland

British Journal of Clinical Pharmacology, EarlyView.
Background Reporting adverse drug reactions (ADRs) is essential for drug safety. In Switzerland, healthcare professionals are legally required to report serious and unlabelled ADRs, yet under‐reporting remains widespread. We tested a novel method to increase reporting of ADR‐related hospitalizations.
Georgia Anita Weber, Sophie‐Charlotte Bartel, Michael Boch, Christoph Rosen, Michael Bodmer, Balthasar Luzius Hug, Thomas Stammschulte, Patrick E. Beeler   +7 more
wiley   +1 more source

Candesartan in nephrological practice

Počki, 2014
First-line drugs in the treatment of hypertension in patients with chronic kidney disease is an angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers.
Ya.A. Dombrovskyi, D.D. Ivanov
doaj   +1 more source

Angiotensin Blockade in Patients with Diabetic Nephropathy [PDF]

, 2007
When used to delay the progression of early nephropathy in patients with type 2 diabetes mellitus, angiotensin receptor blockers (ARBs) are not superior to angiotensin-converting enzyme (ACE) inhibitors.
Jimenez, Julio, Safranek, Sarah
core  

Aldosterone status associates with insulin resistance in patients with heart failure-data from the ALOFT study [PDF]

, 2009
<b>Background</b>: Aldosterone plays a key role in the pathophysiology of heart failure. In around 50% of such patients, aldosterone 'escapes' from inhibition by drugs that interrupt the renin-angiotensin axis; such patients have a worse ...
Connell, J.M.C., Freel, E.M., Latini, R., Lewsey, J.D., Maggioni, A.P., McMurray, J.J.V., Pitt, B., Solomon, S., Tsorlalis, I.K.   +8 more
core   +1 more source

Impact of empiric potassium supplementation on mortality, sudden cardiac arrest and stroke in furosemide initiators

British Journal of Clinical Pharmacology, EarlyView.
Aim A prior non‐randomized study suggests that potassium supplementation may improve survival among furosemide initiators, and a randomized trial suggests that salt substitutes containing potassium might lower stroke risk. We conducted a retrospective cohort study using health‐care data to confirm or refute these associations among new users of ...
Thanh Phuong Pham Nguyen, Sean Hennessy, Colleen M. Brensinger, Warren B. Bilker, Laura M. Dember, Todd A. Miano, Tat‐Thang Vo, Allison W. Willis, Charles E. Leonard   +8 more
wiley   +1 more source

Aldosterone, aldosterone receptor blockers and chronic kidney disease

Zdravniški Vestnik, 2011
Chronic kidney disease (CKD) is a worldwide public health problem and an important risk factor for cardiovascular events, morbidity and mortality. The renin-angiotensin-aldosteron system (RAAS) drugs, angiotensin-converting enzyme inhibitors and/or ...
Sebastjan Bevc
doaj